Qubit Pharmaceuticals Competitors and Similar CompaniesClear all
Evaxion Biotech's competitors and similar companies include ImmunoGen.
 Evaxion Biotech Evaxion Biotech A/S is a company focused on the development of vaccines against cancer and infectious diseases. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. | |
Founding Date | Founding Date 2008 | Founding Date 1981 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations København, DK HQ | Locations Waltham, US HQ |
Employees | Employees 558% decrease | Employees 277161% increase |
Valuation ($) | Valuation ($) 16.2 m | Valuation ($) 8.7 b |
Financial | ||
Revenue (est.) | Revenue (est.) $7.5m (FY, 2025) | Revenue (est.) $108.8m (FY, 2022) |
Cost of goods | Cost of goods N/A | Cost of goods $176k (FY, 2022) |
Gross profit | Gross profit $7.5m (FY, 2025) | Gross profit $108.6m (FY, 2022) |
Net income | Net income ($7.7m) (FY, 2025) | Net income ($222.9m) (FY, 2022) |
Operating ⚠ | ||
Patent Applications | Patent Applications 34 (Feb, 2021) | Patent Applications 600 (FY, 2020) |
Patents Issued | Patents Issued 12 (Feb, 2021) | Patents Issued 1.4 k (FY, 2020) |
Funding | ||
Total funding raised | Total funding raised $ 17m | Total funding raised $ 56m |
For sources of this data, please see the company profile
View Company Profiles
ImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View company